Lipid Nanoparticle Formulation of Niclosamide (nano NCM) Effectively Inhibits SARS-CoV-2 Replication
Overview
Authors
Affiliations
As exemplified by the COVID-19 pandemic, highly infective respiratory viruses can spread rapidly in the population because of lack of effective approaches to control viral replication and spread. Niclosamide (NCM) is an old anthelminthic drug (World Health Organization essential medicine list) with pleiotropic pharmacological activities. Several recent publications demonstrated that NCM has broad antiviral activities and potently inhibits viral replication, including replication of SARS-CoV-2, SARS-CoV, and dengue viruses. Unfortunately, NCM is almost completely insoluble in water, which limits its clinical use. We developed a cost-effective lipid nanoparticle formulation of NCM (nano NCM) using only FDA-approved excipient and demonstrated potency against SARS-CoV-2 infection in cells (Vero E6 and ACE2-expressing lung epithelium cells).
Revisiting Niclosamide Formulation Approaches - a Pathway Toward Drug Repositioning.
Jug M, Laffleur F, Millotti G Drug Des Devel Ther. 2024; 18:4153-4182.
PMID: 39308694 PMC: 11416123. DOI: 10.2147/DDDT.S473178.
Insight into Preventing Global Dengue Spread: Nanoengineered Niclosamide for Viral Infections.
Rejinold N, Jin G, Choy J Nano Lett. 2024; 24(46):14541-14551.
PMID: 39194045 PMC: 11583367. DOI: 10.1021/acs.nanolett.4c02845.
Kim T, Jung W, Cho S, Kim G, Yun H, Chae J Clin Transl Sci. 2024; 17(5):e13833.
PMID: 38797873 PMC: 11128490. DOI: 10.1111/cts.13833.
Niclosamide - encapsulated lipid nanoparticles for the reversal of pulmonary fibrosis.
Yu Y, Liu H, Yuan L, Pan M, Bei Z, Ye T Mater Today Bio. 2024; 25:100980.
PMID: 38434573 PMC: 10907778. DOI: 10.1016/j.mtbio.2024.100980.
Zhang H, Gerasimovskaya E, McCarthy M, May N, Prasad R, Riddle S Am J Respir Cell Mol Biol. 2023; 69(2):210-219.
PMID: 37071849 PMC: 10399142. DOI: 10.1165/rcmb.2022-0373OC.